p-tau drug
Evidence from:
primary |
all sources
Related entities (11)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| apoE | regulates | p-tau | — | 1 |
| apoE4 | regulates | p-tau | — | 1 |
| apoE4 | risk_factor_for | p-tau | — | 1 |
| apoE4 | associated_with | p-tau | — | 1 |
| Aβ accumulation | regulates | p-tau | — | 1 |
| p-tau | biomarker_for | Alzheimer's disease | — | 2 |
| p-tau | risk_factor_for | cognitive decline | — | 1 |
| p-tau | expressed_in | GABA | — | 1 |
| p-tau | risk_factor_for | memory | — | 1 |
| p-tau | expressed_in | neuronal cultures | — | 1 |
| p-tau | expressed_in | neurons | — | 1 |
Mentioned in (4)
Papers in which this entity is mentioned.
- Human 3D brain organoids: steering the demolecularization of brain and neurological diseases. (2023)
- Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease. (2021)
- Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. (2018)
- Early pathogenic event of Alzheimer's disease documented in iPSCs from patients with PSEN1 mutations. (2017)
Merged raw entities (1)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| p-tau | drug | 4 | 6 |